News AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.
News NICE backs new drugs for Crohn's disease, lymphoma Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.
News Concentra throws lifeline to troubled CARGO Therapeutics After cutting staff and halting development of its CAR-T therapies, CARGO has agreed to a takeover by Kevin Tang's Concentra Bio.
News New radiopharma Actithera emerges with $75.5m in financing A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.
News J&J bids to extend prostate cancer uses for Akeega J&J is hoping the AMPLITUDE study results will make Akeega the first drug in the PARP inhibitor class for castration-sensitive prostate cancer.
News AZ claims EU okay for Imfinzi in bladder cancer AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.
News FDA names a new CDER director, choosing a biotech vet The FDA has rounded out its senior leadership by naming biopharma industry executive George Tidmarsh to the role of CDER director.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face